# A therapeutic vaccine to clear cervical precancer without surgery

Source: https://onco.cc/ideas/idea-prev-therapeutic-hpv-vaccine-cin/  
OnCo record `idea-prev-therapeutic-hpv-vaccine-cin` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Precancer is treated by cutting away part of the cervix, which raises pregnancy risks. A vaccine that makes the immune system clear the infected cells would avoid surgery.

## Summary

Cervical precancer is treated by cutting away part of the cervix, which raises pregnancy risks, so this idea develops next-generation therapeutic vaccines, mRNA or E6/E7-targeted, that make the immune system clear CIN2/3 lesions, aimed first at women planning pregnancy. HPV oncoproteins are foreign antigens present in every lesion cell, and DNA vaccines such as VGX-3100 have already shown partial efficacy. Endpoints would be histological regression and HPV clearance at six months, allowing surgery to be avoided. The test is a phase 2b RCT of 400 women with a regression endpoint. At early-clinical maturity it addresses the bottlenecks Prevention we already have is not deployed and Overdiagnosis and false alarms, and relates to Cancer interception vaccines for high-risk carriers.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A therapeutic HPV vaccine achieves at least 50% histological regression with viral clearance at six months in CIN2/3, allowing surgery to be avoided in half of treated women.
- Rationale: HPV oncoproteins are foreign antigens present in every lesion cell, and partial efficacy is already proven.
- Proposed test: Run a phase 2b RCT of 400 women with a regression endpoint.
- Maturity: early-clinical
- Actor: industry

## Sources

- Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018): https://doi.org/10.3322/caac.21440

## Connected records

- ideas: [Cancer interception vaccines for high-risk carriers](https://onco.cc/ideas/idea-interception-vaccines/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/)
- bottlenecks: [Overdiagnosis and false alarms](https://onco.cc/bottlenecks/b-overdiagnosis/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States](https://onco.cc/key-papers/paper-islami-ca-cancer-j-clin/)

---
JSON: https://onco.cc/api/v1/entities/idea-prev-therapeutic-hpv-vaccine-cin.json